Rapid Health allegedly submitted false claims to Medicare for over-the-counter COVID-19 tests that were not provided to Medicare beneficiaries.

Foresight said Roche failed to bring its trade-secret causes of action within the three-year statute of limitations.

NEW YORK — Laboratory-developed tests, FDA actions, the JP Morgan Healthcare Conference, and Roche — perhaps not surprisingly these subjects dominated the attention of 360Dx readers in 2024. Reader ...

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

NEW YORK – For clinical labs, 2024 will most likely be remembered as the year the US Food and Drug Administration finally made good on its decades-old promise — or threat, depending on your point of ...

NEW YORK – Diagnostics firm Fujirebio and drugmaker Eisai said Monday that they have entered a memorandum of understanding for research into and use of blood-based biomarkers for neurodegenerative ...

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.